
Background The adoption of precision medicine in antihypertensive treatment remains challenging, largely because of substantial interindividual variability in drug response. This study aimed to determine whether genotyping combined with Bayesian machine-learning methods could improve the prediction of response to amlodipine. Methods We conducted a multicenter prospective cohort study of 292 Chinese patients with hypertension treated with amlodipine. Eight single-nucleotide polymorphisms (SNPs) in key pharmacokinetic and pharmacodynamic pathways were sequenced. After excluding two SNPs with insufficient variation, six SNPs were integrated with clinical variables to develop prediction models. The outcome, blood pressure control as a measure of treatment efficacy, was defined as achieving office SBP less than 140 mmHg and DBP less than 90 mmHg after treatment. Using a rigorous validation framework, we compared Bayesian Additive Regression Trees (BART) with Random Forest Classification (RFC) and Bayesian linear modeling through repeated cross-validation and external validation. Results At the rs5065 locus, 217 individuals (99.5%) carried the wild-type genotype, and rs2740574 was exclusively homozygous for the mutant allele. Therefore, only the remaining six SNPs were used for model development, comparison, and evaluation. The BART model achieved an external validation area under the receiver operating characteristic curve (AUC) value of 0.846, notably outperforming RFC (AUC = 0.61) and Bayesian linear models (AUC = 0.644–0.665). Conclusion BART substantially improves prediction of blood pressure control in patients with hypertension treated with amlodipine monotherapy. Integrating pharmacogenomic data with advanced Bayesian machine learning offers a robust framework for personalized antihypertensive therapy.
Background Mycophenolic acid (MPA) is a key immunosuppressant for lupus nephritis (LN), yet therapeutic response varies widely among individuals. Genetic variation in UGT1A9 , particularly the -2152C>T promoter polymorphism, may influence MPA metabolism and exposure. Most existing pharmacogenomic studies have focused on solid organ transplant recipients, while evidence in autoimmune diseases, especially among Southeast Asian populations, remains limited. This study aimed to evaluate the association between the UGT1A9 -2152C>T promoter polymorphism and MPA treatment response in Indonesian patients with LN. Methods A case–control study was conducted among 74 patients with LN receiving MPA therapy. Treatment response was classified as responders (n = 45) or non-responders (n = 29) based on the Systemic Lupus Erythematosus Disease Activity Responder Index-50 (SRI-50). Genotyping of the UGT1A9 -2152C>T polymorphism was performed using polymerase chain reaction–restriction fragment length polymorphism. Results No significant differences in genotype frequencies or allele distribution were observed between responders and non-responders ( P > 0.05). The T allele frequency was 11.5% and was not significantly associated with treatment response. Conclusion UGT1A9 -2152C>T showed no significant association with MPA response in Indonesian LN patients. These findings provide initial local pharmacogenomic evidence and underscore the need for larger multi-gene studies to support genotype-guided MPA therapy.
OBJECTIVES:Genetic variation has been proposed as a potential contributor to antidepressant nonresponse, but its role in treatment-resistant depression (TRD) remains unclear. This study used pharmacogenetics (PGx) to characterize genetic variation in TRD and determine whether actionable PGx variation and drug-gene interaction (DGI) mismatch were associated with antidepressant nonresponse and TRD burden. METHODS:This observational study included 158 individuals with TRD recruited from outpatient clinics in Western Australia. Genotype and genotype-predicted phenotypes for CYP2B6, CYP2C19, and CYP2D6 were derived from commercial PGx testing and compared with ethnicity-matched reference populations from ClinPGx. Antidepressant-specific DGIs were classified as actionable or nonactionable according to Clinical Pharmacogenetics Implementation Consortium guidelines, and unsupervised clustering was used to identify clusters based on these actionability profiles. Analyses were performed to determine if actionable PGx variation, cluster membership, or PGx mismatch was associated with TRD burden (number of failed antidepressant trials). RESULTS:PGx variation in the TRD cohort was consistent with population expectations, with no evidence of enrichment for actionable PGx variants. Clustering identified six clusters with distinct and gene-specific patterns of PGx variation independent of demographic and clinical characteristics. However, neither PGx mismatch nor cluster membership were associated with TRD burden. CONCLUSION:These findings suggest that actionable PGx phenotypes are neither enriched in TRD nor associated with greater TRD severity. Rather, the results indicate that TRD does not represent a single, unified PGx-predicted 'poor pharmacological responder' phenotype but instead reflects a biologically heterogeneous collection of distinct PGx profiles.
Methotrexate (MTX) treatment of juvenile idiopathic arthritis (JIA) is complicated by severe intolerance in approximately 30% of patients. MTX intolerance typically presents as nausea (anticipatory and postdose), vomiting, and behavioral symptoms. Although genetic variants in SLCO1B1 have been associated with MTX toxicity in retrospective studies of inflammatory bowel disease, prospective evaluation of this relationship in JIA patients is lacking. This study examined SLCO1B1-MTX intolerance associations accounting for clinical covariates in a prospective observational cohort of patients receiving standard weekly MTX doses (5-25 mg/m2). We performed a zero-inflated Poisson analysis using forward stepwise inclusion of clinical covariates followed by SLCO1B1 alleles. Among 217 JIA patients who completed the MTX Intolerance Severity Score (MISS) survey at 6 ± 2 months post-MTX initiation, the cohort was predominantly female (69.1%), White (76.5%), and received supplementation with folic acid (70.5%). Over 30% of patients met the threshold for MTX intolerance (MISS ≥ 6), and 62.7% of patients reported any MTX intolerance symptoms (MISS > 0). The SLCO1B1*37 allele was associated with lower odds of MISS > 0 (odds ratio = 0.60, P = 0.046) and a lower reported MISS score (incidence rate ratio = 0.74, P < 0.001) among individuals with non-zero intolerance, suggesting protection from MTX intolerance symptoms. These associations were consistent in sensitivity analyses stratified by folic acid supplementation. Further validation of these findings is needed to support future pharmacogenetic-guided MTX dosing strategies, including evaluation of other SLCO1B1 alleles.
OBJECTIVES:Clinical trial evidence is scarce for optimal antiplatelet strategies in patients undergoing intracranial artery stenting with CYP2C19 loss‑of‑function alleles, especially regarding the efficacy‑safety balance. METHODS:This single‑center retrospective study enrolled patients receiving genotype‑guided antiplatelet regimens for intracranial stenting between January and December 2023, with 6‑month follow‑up. Clinical outcomes were compared across CYP2C19 phenotypes. RESULTS:Among 205 patients, 46.8% were normal metabolizers, 40.5% intermediate metabolizers, and 12.7% poor metabolizers. Aspirin-clopidogrel was prescribed for all normal metabolizers, 80.7% intermediate metabolizers, and 19.2% poor metabolizers. No intergroup differences were observed in risks of ischemic stroke/transient ischemic attack (TIA), cardiovascular events, intracerebral hemorrhage (ICH), or any bleeding (all P > 0.05). In intermediate metabolizers and poor metabolizer subgroups, ischemic stroke/TIA rates were 11.1% in the aspirin-clopidogrel group and 9.68% in the aspirin-ticagrelor group, with no significant difference compared to normal metabolizers (4.17%). ICH rates were 1.39% in the aspirin-clopidogrel group and 6.45% in the aspirin-ticagrelor group, showing no significant difference versus normal metabolizers (1.04%). Multivariate logistic analysis found the number of stents (odds ratio [OR] = 2.70; 95% confidence interval [CI] = 0.89-6.95; P = 0.043) was a risk factor for ischemic stroke/TIA. Ticagrelor-based dual antiplatelet therapy (DAPT; OR = 10.57; 95% CI = 1.00-111.7; P = 0.05) and baseline l ow-density lipoprotein cholesterol (LDL-C; OR = 7.22; 95% CI = 1.80-29.01; P = 0.005) were associated with ICH risk. CONCLUSION:Antiplatelet regimens were adjusted for a subset of intermediate metabolizers and poor metabolizers prior to stenting, and the 6-month clinical outcomes were comparable across normal metabolizers, intermediate metabolizers, and poor metabolizers. The stent number was associated with ischemic stroke/TIA risk; baseline LDL-C and ticagrelor-based DAPT with ICH risk. These exploratory findings need validation in adequately powered studies.